GSK Studentships
Global biopharma company GSK is investing up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer. The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, aimed at exploring the potential of cancer prevention through vaccination.
The programme leverages the complementary expertise of GSK and Oxford in the science of the immune system, vaccine development and cancer biology. It is hoped that the insights generated through the programme into how cancer develops could inform new approaches to vaccination for cancer prevention, offering fresh hope in the fight against the disease.
There will be a number of GSK-Oxford DPhil studentships available for the 2026 intake. Further details on how to apply will be added to this page when applications open in September.